Similarly, the phase 2 trial by Jones et al. (2020) provided evidence of improved progression-free survival with the combination of fulvestrant and capivasertib in metastatic estrogen receptor-positive breast cancer, compared to placebo [3]. The gene discussed is ESR1; the disease is breast cancer.